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Teratogenicity can be predicted in vitro using the embryonic
stem cell test (EST). The EST, which is based on the
morphometric measurement of cardiomyocyte differentiation
and cytotoxicity parameters, represents a scientiﬁcally validated
method for the detection and classiﬁcation of chemicals according
to their teratogenic potency. Furthermore, an abbreviated protocol
applying ﬂow cytometry of intracellular marker proteins to deter-
mine differentiation into the cardiomyocyte lineage is available.
Although valproic acid (VPA) is in worldwide clinical use as
antiepileptic drug, it exhibits two severe side effects, i.e.,
teratogenicity and hepatotoxicity. These limitations have led to
extensive research into derivatives of VPA. Here we chose VPA as
model compound to test the applicability domain and to further
evaluate the reliability of the EST. To this end, we study six closely
related congeners of VPA and demonstrate that both the standard
and the molecular ﬂow cytometry-based EST are well suited to
indicate differences in the teratogenic potency among VPA analogs
that differ only in chirality or side chain length. Our data show that
identical results can be obtained by using the standard EST or a
shortened protocol based on ﬂow cytometry of intracellular marker
proteins. Both in vitro protocols enable to reliably determine
differentiation of murine stem cells toward the cardiomyocyte
lineage and to assess its chemical-mediated inhibition.
Key Words: valproic acid; congeners; embryonic stem cell test;
structure-activity relationships; embryotoxicity; teratogenicity.
Testing for reproductive and developmental toxicity of drugs
and other chemical compounds in vitro is an attractive
alternative procedure to time-consuming and expensive
in vivo or ex vivo experiments (Spielmann, 2009). The
embryonic stem cell test (EST) employs the blastocyst-derived
embryonic stem cell line D3 from mice that spontaneously
differentiates into contracting cardiomyocytes in cell aggre-
gates, termed embryoid bodies (EBs). This morphological
feature is used as an endpoint for differentiation together with
the measurement of cytotoxicity in D3 cells and 3T3 ﬁbroblasts
in the standard EST (Seiler et al., 2006; Spielmann et al.,
1997). In an international validation study supported by the
European Center for the Validation of Alternative Methods
(ECVAM), this method proved reliable for the prediction of
embryotoxicity in vivo (Genschow et al., 2004). For a set of 20
reference compounds with different embryotoxic potencies
in vivo of nonembryotoxic, weakly embryotoxic, and strongly
embryotoxic, the EST provided correct classiﬁcation in 78% of
all cases. Remarkably, a predictivity of 100% was obtained for
strong embryotoxicants. However, in a second evaluation study
set up to enlarge the database, only 2 out of 13 previously
untested compounds were classiﬁed correctly, thus highlighting
the limitations of the prediction model (PM, Marx-Stoelting
et al.,2 0 0 9 ). A detailed review of these data is currently in
progress at ZEBET. Preliminary analysis suggests that some of
the misclassiﬁcation might be because of different classiﬁca-
tion rules in the validation and postvalidation study applied by
the experts to assign the chemicals to the embryotoxicity
classes according to their in vivo potencies.
After validation of the EST, many research groups were
interested in reﬁning the EST protocol toward a more rapid and
molecular-based assay to allow for quantiﬁcation of drug effects
on the cellular level as well as for higher throughput analysis.
Recently, we reported on an abbreviated, molecular-based EST
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ferentiation were selected to substitute for visual evaluation
of contracting cell areas as a toxicological endpoint. In this
improved EST protocol (referred to as molecular FACS-EST),
both viability and the expression of the sarcomeric myosin
heavy chain (aMHC) protein are quantiﬁed in differentiating
cells while being continuously exposed to the test chemical
(Buesen et al., 2009; Seiler et al., 2004). Intracellular ﬂow
cytometry of aMHC expression and concurrent assessment of
cell viability is scheduled at day 7 of differentiation.
In drug development, late-stage attrition of newly developed
drug candidates partly because of unexpected safety reasons is
a critical issue (Kola and Landis, 2004). Methods that can be
implemented in early-stage drug research and development to
assess safety issues such as developmental toxicity would
signiﬁcantly decrease the ﬁnancial burden of discovering and
introducing new drugs to the market. In recent years, the EST
has been evaluated by the pharmaceutical industry for testing
during research and development and considerable efforts
have been made to improve the EST for this purpose
(Augustine-Rauch et al., 2010; Paquette et al., 2008; Whitlow
et al., 2007). To develop more efﬁcient or less adverse
derivatives of a lead compound, small modiﬁcations such as
stereochemical isomerization or side chain variation are in-
troduced to the structure of the parent compound. Ideally, the
resulting substance library would be tested for possible adverse
effects in addition to its intended pharmacological action to
identify the most promising candidates for further development.
To evaluate the applicability of the EST to assess such
structure-activity relationships (SAR), we chose valproic acid
(VPA) as a model compound because it is a teratogenic drug
with a large number of tested congeners (Eikel et al., 2006b;
Isoherranen et al., 2003). VPA is one of the most frequently
used antiepileptic drugs worldwide. Additionally, it has
recently been approved for migraine prophylaxis (Calabresi
et al., 2007) and is used in the treatment of bipolar disorders
(Bowden, 2009). Moreover, it is being investigated for treat-
ment of cancer (Batty et al.,2 0 0 9 ), Alzheimer’s disease (Tariot
et al., 2002), and latent human immunodeﬁciency virus
infections (Lehrman et al., 2005). Two severe side effects of
VPA, hepatotoxicity (Lheureux and Hantson, 2009), and
teratogenicity (Ornoy, 2009) have led to research into
derivatives of VPA. The embryotoxic effect of VPA has been
ascribed to malformation of the heart and defects in neurulation
(Ornoy, 2009). In addition, craniofacial and skeletal anomalies
and behavioral deﬁcits have been reported. VPA has been
shown to inhibit histone deacetylases in vitro (Phiel et al.,
2001). Histone deacetylases are crucial enzymes involved in
chromatin remodeling, and this may explain the multiple
effects of VPA on embryonic development and why it may be
a promising anticancer drug.
We chose six closely related analogs of VPA whose
teratogenic potency has been determined in vivo in the Naval
Medical Research Institute (NMRI)-exencephaly-mouse model
(Fig. 1)( Eikel et al., 2006b). For this in vivo assay, the
compounds are injected into pregnant NMRI mice, and after 10
days, the animals are sacriﬁced, the uteri removed, and the
number of implants and resorptions are counted. Individual
fetuses are weighed and inspected for external malformations,
and the exencephaly rate is calculated relative to the number of
live fetuses (Eikel et al., 2006b).
In a collaborative study supported by the German Ministry
for Education and Research (BMBF), with two partners from
the pharmaceutical industry, Bayer Schering Pharma AG and
Nycomed GmbH, we evaluate the applicability domain of both
the EST and the FACS-EST using these six closely related
compounds (Fig. 1). These VPA congeners exhibit varying
teratogenic potencies resulting from introduction of minute
changes at the chiral center, change of position of a methyl
group, addition of an ethyl group, and introduction of a triple
carbon bond (acetylenic moiety) (Fig. 1)( Eikel et al., 2006b).
Here, we demonstrate the potency of the EST and FACS-EST
to distinguish among these similar structures.
MATERIALS AND METHODS
VPA derivatives. 2-Ethyl-4-methylpentanoic acid (2-EMP, 144.2 g/mol),
2-isobutyl-4-pentynoic acid (2-IP, 154.2 g/mol), (R)-2-propyl-4-pentynoic acid
(RProP, 140.2 g/mol), (S)-2-propyl-4-pentynoic acid (SProP, 140.2 g/mol), (R)-
FIG. 1 Chemical structures of the VPA derivatives investigated in this
study and their teratogenic potencies in vivo determined in the NMRI-
exencephaly-mouse model. Teratogenicity rating (0, þ, þþþ, and þþþþþ)
according to Eikel et al. (2006b). 2-EMP and 2-IP were applied as mixtures of
both stereoisomeric forms (racemates), whereas all alkyne derivatives used
were enantiomerically pure compounds; ‘‘*’’ Denotes a chiral center.
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acid (SPenP, 168.2 g/mol) (Fig. 1) were synthesized as described in detail
elsewhere (Bojic et al., 1996 and references therein). Their teratogenic
potencies in vivo have been determined in the NMRI-exencephaly-mouse
model and rated as described (Eikel et al., 2006b; Hauck and Nau, 1992). VPA
(144.2 g/mol) was purchased from Sigma (Taufkirchen, Germany). All
chemicals were dissolved in dimethyl sulfoxide (Sigma). Final solvent
concentrations applied showed no undesired background effect in differenti-
ation and viability assays (Seiler et al., 2006).
Cell culture. The undifferentiated murine embryonic stem cell line D3
(Doetschman et al., 1985) was cultured in high glucose (4.5 g/l) Dulbecco’s
modiﬁed Eagle’s medium (DMEM; Gibco Invitrogen, Karlsruhe, Germany)
containing 15% fetal calf serum (different sources and batches of embryonic
stem cell-qualiﬁed fetal bovine serum were screened for suitability for the
EST), 2mM glutamine, 50 U/ml penicillin, 50 lg/ml streptomycin, 1%
nonessential amino acids (Gibco Invitrogen), 0.1mM b-mercaptoethanol
(Sigma), and 1000 U/ml murine leukemia inhibitory factor (mLIF; Chemicon,
Hofheim, Germany). Only cells in passages 6–24 after thawing were used in the
experiments. BALB/c 3T3 ﬁbroblasts (clone A31, ICN Flow, Eschwege,
Germany) were grown in DMEM supplemented with 10% fetal calf serum,
4mM glutamine, 50 U/ml penicillin, and 50 lg/ml streptomycin. Cells were
maintained in 5% CO2 and 95% humidity at 37C and were routinely passaged
every 2–3 days.
Differentiation assay. Differentiation assays were performed to detect
compound-induced adverse effects on the differentiation of D3 cells into
contracting cardiomyocytes. The method has been described in detail for the
validated differentiation assay (Seiler et al., 2006; Spielmann et al., 1997). The
modiﬁed protocol using intracellular ﬂow cytometry of selected marker
proteins as molecular endpoints of differentiation is described elsewhere
(Buesen et al., 2009; Seiler et al., 2006) and in brief below under ‘‘Flow
cytometry’’ section.
Brieﬂy, 750 D3 cells in 20 ll of supplemented DMEM without mLIF (to
allow differentiation) were placed as hanging drops on the lid of a dish ﬁlled
with PBS (Sigma) and incubated for 3 days at 37C, 5% CO2, and 95%
humidity in the presence of test chemicals at various concentrations. During
this period, the cells form aggregates referred to as EBs. Subsequently, the EBs
were transferred to uncoated dishes (Greiner, Frickenhausen, Germany) to
avoid attachment, containing the appropriate concentration of the test chemical
for another 2 days. On day 5, EBs were plated separately into the wells of a 24-
multiwell tissue culture plate (BD Falcon, Erembodegem, Belgium), containing
the appropriate concentration of test chemical, to allow adherence and
outgrowth of the EBs and development of spontaneously beating cardiac
muscle cells. On day 10 of the assay, differentiation into contracting myocardial
cells is determined using direct phase contrast microscopy. Each well of the 24-
well plate is inspected, and the number of wells containing any spontaneously
contracting cells is recorded. Individual experiments were considered valid
when solvent control plates exhibited beating cardiomyocytes in at least 21 out
of 24 wells. From the concentration-response relationship, the half maximum
inhibitory concentration of differentiation of D3 cells (ID50(D3)) value was
derived as the concentration of 50% reduction in the number of differentiated
EBs compared with solvent controls (see ‘‘Data analysis and statistics’’ section
below).
Flow cytometry. Cell dissociation and intracellular staining for ﬂow
cytometry analyses were carried out as previously described (Buesen et al.,
2009; Seiler et al., 2004, 2006). Brieﬂy, EB formation was induced as
described above, and EBs were transferred into uncoated dishes after 3 days.
On day 7 of differentiation, EBs were dissociated using trypsin/EDTA. The
cells were ﬁxed with 2% paraformaldehyde in PBS (pH 7.4), permeabilized
with 0.15% saponin in PBS, and treated with 10% normal goat serum to block
nonspeciﬁc antigens. For immunostaining, the cells were incubated for 1 h on
ice with primary monoclonal antibodies against sarcomeric aMHC (clone
MF20 concentrate, Hybridoma Bank, University of Iowa, see also Bader et al.,
1982) diluted 1:1600 in blocking solution (PBS/10% goat serum/1%
bovine serum albumin/0.15% saponin). After washing, cells were incubated
for 30 min on ice with biotin-conjugated goat anti-mouse immunoglobulin
G (1:1000, Dianova, Hamburg, Germany) followed by incubation on ice with
R-phycoerythrin–conjugated streptavidin (1:600, Dianova) for 15 min. The
cells were analyzed in a ﬂow cytometer at 585 nm. For each experiment, 10
4
viable cells were analyzed; nonviable cells were excluded by appropriate
gating. On day 7 of differentiation, 10–20% of the untreated viable cell
populations were aMHC positive. Untreated cells and cells lacking primary
antibody were used as controls. All data analyses were carried out using
CellQuest software (Becton Dickinson, Erembodegem, Belgium). From the
concentration-response relationships, the ID50(D3) value was derived as the
concentration of 50% reduction in the number of aMHC-positive cells
compared with solvent controls (see below).
Determination of cytotoxicity. Cytotoxic effects on D3 cells and 3T3
ﬁbroblasts were determined using the 3-(4,5-di-methylthiazol-2-yl)-2,
5-diphenyl tetrazolium bromide (MTT) assay (Mosmann, 1983) either at
experimental day 10 of the validated EST or at day 7 of the FACS-EST, as
described previously (Seiler et al., 2004, 2006). Brieﬂy, 500 cells were seeded
into each well of a 96-well microtiter plate (BD Falcon) and grown in
supplemented DMEM without mLIF in the presence of the test compound. A
negative control with solvent diluted in medium was included. After 7 and 10
days of culture and two changes of medium (containing the appropriate
concentration of test chemical) at days 3 and 5, MTT (Sigma) was added
followed by incubation for 2 h. The conversion into a dark blue formazan
product was quantiﬁed spectrophotometrically by measuring the absorbance at
a wavelength of 570 nm and subtraction of the absorbance at 630 nm using
a microplate ELISA reader. From the concentration-response relationships, the
half maximum inhibitory concentration of growth of D3 cells (IC50(D3)) and
3T3 cells (IC50(3T3)) values were derived as the concentration of 50%
reduction in the absorbance compared with solvent controls (see below).
Data analysis and statistics. Endpoints for differentiation and cytotoxicity
were determined for each compound in the three different laboratories with at
least two independent runs each. The relationship between the substance
concentration x (millimolar) and the blank-subtracted response y was analyzed
in terms of a three-parameter logistic function
yðxÞ¼
d
1 þ exp½bðlnx   eÞ 
;
where d represents the upper asymptote and e is the natural log-transformed
concentration producing a response halfway between the upper asymptote and
zero. The parameter b denotes the relative slope around e. The concentration x50
(millimolar) at which y decreased to 50% of the mean response under control
condition (ycontrol) was derived from the model parameters according to
x50 ¼ expðeÞ

d   0:5ycontrol
0:5ycontrol
1
b
:
Depending on the experimental context, the x50 represented the concentra-
tion for a 50% reduction in the number of differentiated EBs [ID50(D3)], in
aMHC expression [ID50(D3)], or of the viability of D3 cells [IC50(D3)] and
3T3 cells [IC50(3T3)]. For each endpoint, a two-way ANOVA was performed
using the log10-transformed x50 as response variable and the ‘‘compound’’ and
‘‘laboratory’’ as factors. An interaction term ‘‘compound 3 laboratory’’ was
additionally included into the model. The ﬁtted parameter values were used to
derive estimates and 95% conﬁdence intervals for each compound. Multiple
comparisons between the compound-speciﬁc half maximum effective concen-
tration (ID50 or IC50) estimates (log10 scale) were performed by Tukey’s
method for all pairwise differences in combination with robust procedure that
accounted for heterogeneous variances and unbalanced group sizes (Herberich
et al., 2010). Differences between means were regarded as signiﬁcant at a value
of p < 0.05.
The curve ﬁtting and subsequent statistical analyses were performed in the R
statistical computing environment (R Development Core Team, 2009)i n
362 RIEBELING ET AL.combination with the drc package (Ritz and Streibig, 2005). Multiple comparisons
were performed by using the multcomp package (Hothorn et al., 2008).
The effect concentrations for the three endpoints were entered into the PM
of the EST (Seiler et al., 2006) after appropriate conversion from molar to mass
concentration. The PM was originally expressed in terms of Fisher’s
classiﬁcation functions (functions I, II, and III; Scholz et al., 1999), which
permit the assignment to one of the three toxicity classes. In order to obtain
a gradual ranking of the VPA congeners within the three predicted toxicity
classes and also to associate this ranking with the substances of the
prevalidation and validation study (Genschow et al., 2004; Scholz et al.,
1999), we have instead chosen to express the PM in terms of the two canonical
discriminant functions (Green, 1979), LD1 and LD2,
LD1 ¼  0:879log10IC3T3
50   0:819log10ICD3
50 þ 0:967
IC3T3
50  ID50
IC3T3
50
þ 2:31
LD2 ¼ 0:265log10IC3T3
50   0:595log10ICD3
50   0:947
IC3T3
50  ID50
IC3T3
50
þ 0:264:
The classiﬁcation and gradual ranking of the VPA congeners are
subsequently visualized in a so-called canonical plot. The coefﬁcients of the
two canonical discriminant functions were calculated in the R statistical
computing environment (R Development Core Team, 2009) by using the lda
function of the MASS package (Venables and Ripley, 2002) and the published
EST data of the prevalidation set (Genschow et al., 2004). The decision
boundaries in the canonical plot were calculated as described (Venables and
Ripley, 2002).
Study design. This collaborative study was performed in three independent
laboratories, ZEBET, Bayer Schering Pharma AG, and Nycomed GmbH.
Initially, the interlaboratory variance was evaluated using three substances,
5-ﬂuorouracil, 6-aminonicotinamide, and VPA, which had been previously
tested in the validation study (Genschow et al., 2004). No signiﬁcant difference
between the laboratories was found for any given endpoint.
Similarly, for the subsequent testing of the VPA congeners, the overall
interlaboratory variance (r) of the log10-transformed effect concentration was
r < 0.18 for the morphological determination of differentiation and r < 0.11
for cytotoxicity measurements of all substances. The intralaboratory variance
was higher with r < 0.25 for the differentiation assay, whereas the variance in
cytotoxicity was r < 0.16.
RESULTS
Structure and In Vivo Potency of VPA Derivatives
The structures of the compounds tested are given in Figure 1.
VPA, a branched short-chain carboxylic acid with two propyl
chains at the a-carbon, is the lead compound and was graded as
exhibiting medium teratogenic potency (þþþ) in the NMRI-
exencephaly-mouse model (Eikel et al., 2006b). In vitro, it was
correctly predicted as weakly embryotoxic by the EST in the
validation study (Genschow et al., 2002, 2004), in line with its
in vivo embryotoxicity (Brown, 2002).
The teratogenic potency in vivo mentioned hereafter for all
compounds refers to results obtained by the NMRI-exence-
phaly-mouse model as reported by Eikel et al. (2006b). 2-EMP
has one isobutyl and one ethyl chain at the a-carbon and was
used as racemic mixture. It was rated having no detectable
teratogenic potency (0). Similarly, 2-IP, containing one
isobutyl and one propynyl chain, was also used as racemate
but exhibited weak teratogenicity (þ). The alkyne derivatives
originally were developed to abolish the hepatotoxicity of VPA
caused by the metabolic intermediates 4-ene-VPA and 2,4-
diene-VPA (Kassahun and Abbott, 1993). RProP and SProP
have one propyl and one propynyl chain. The (R)-enantiomer
was graded as of low teratogenicity (þ), whereas the (S)-
enantiomer exhibited very strong teratogenicity (þþþþþ).
RPenP and SPenP have one pentyl and one propynyl chain,
with the (R)-enantiomer graded as medium teratogenic (þþþ),
whereas the (S)-enantiomer exhibited again very high terato-
genicity (þþþþþ).
Inhibition of Differentiation
For the EST, concentration-dependent inhibition of differ-
entiation was determined using cardiomyocyte contraction in
EB outgrowths as an endpoint. D3 cells, initially grown in
a ‘‘hanging drop’’ and then replated as individual EBs, were
treated with different concentrations in the range of 1–1000 lg/
ml of the respective compound for 10 days. The ID50(D3) was
derived from logistic regression analysis of the concentration-
dependent reduction of beating EBs. Figures 2A and 2B show
representative concentration-response curves for the seven
compounds tested. Mean ID50(D3) values are summarized in
Figure 3A, and all ID50 and IC50 values of the EST together
with the 95% conﬁdence intervals are listed in Table 1.
Differentiation was most potently inhibited by SPenP and
SProP, and their ID50(D3) values were more than 30-fold lower
when compared with the least potent compound, 2-EMP (Table
1 and Fig. 3A). Comparing the differentiation endpoint with
the rating of Eikel et al. (2006b) showed that this is in
agreement with the high potency of SPenP and SProP and the
inactivity of 2-EMP in the NMRI-exencephaly-mouse model.
RPenP was 11-fold less potent than its (S)-enantiomer, and
RProP was 17-fold less potent than its (S)-enantiomer (Table
1). This is in good correlation with their in vivo ranking of
FIG. 2 Effects on cardiomyocyte differentiation of D3 cells in response to
exposure against VPA or one of its congeners. Representative curves of
concentration-dependent inhibition of differentiation after 10 days of treatment
are shown in (A) for SProP, VPA, RProP, 2-IP, and 2-EMP and in (B) for
SPenP, VPA, RPenP, 2-IP, and 2-EMP.
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(þþþþþ) for SProP versus (þ) for RProP. The in vitro
potency of 2-IP lies between those of RProP and 2-EMP, in
line with its (þ) rating in vivo (Eikel et al., 2006b). VPA and
RPenP had both been ranked (þþþ) in vivo (Eikel et al.,
2006b); however, in the differentiation assay, VPA was closer
to the (S)-enantiomers and RPenP closer to RProP resulting in
a ﬁvefold difference in their ID50(D3) values (Fig. 3A). The
mean values for VPA were similar to previously reported
ID50(D3) values obtained with the same cell line (Buesen et al.,
2009; Hettwer et al., 2010; Peters et al., 2008). Consequently,
the ID50(D3) values follow a ranking of SProP < SPenP <
VPA << RPenP < RProP < 2-IP < 2-EMP (Table 1).
Cytotoxicity
To test for cytotoxicity, D3 and 3T3 cells were grown in
a monolayer and treated with different concentrations in the
range of 4–2000 lg/ml of the respective compound for 10
days. Viability was determined using the MTT assay, and
IC50(D3) and IC50(3T3) values were derived from logistic
regression analysis of the concentration-dependent reduction of
MTT conversion.
The viability of D3 cells in the presence of the seven
compounds is summarized in Figure 3B, and individual
IC50(D3) values are listed in Table 1. Here, the strongest
congener SPenP was more than 40-fold more potent than the
weakest, 2-EMP. Similar to the differentiation endpoint, (S)-
enantiomers were always more potent than the corresponding
(R)-enantiomers. SPenP was 15-fold more potent than RPenP,
and SProP was eightfold more potent than RProP. In addition,
the longer chain derivatives SPenP and RPenP were four- and
twofold more potent than their propyl chain counterparts SProP
and RProP, respectively; a difference that was not evident in
the differentiation assay. Moreover, VPA had an IC50(D3)
value similar to RPenP, and RProP was similar to 2-IP (Table 1).
Overall, the following ranking according to the IC50(D3) values
emerged: SPenP << SProP << VPA < RPenP << RProP <
2-IP < 2-EMP (Table 1).
FIG. 3 Graphical presentation of ID50 and IC50 values of VPA and its
congeners obtained in the EST. (A) Cardiomyocyte differentiation of D3 cells
assessed on day 10 of differentiation by morphological evaluation. Viability
was measured using the MTT assay after 10 days of treatment of (B) D3 cells
and (C) 3T3 cells. Compound-speciﬁc ID50 and IC50 values (means ± 95%
conﬁdence interval) were derived from experiments performed by three
different laboratories in at least two independent experiments each.
TABLE 1
Mean Values and 95% Conﬁdence Interval (Upper and Lower
Bound) of the EST Derived from Experiments Performed in
Three Independent Laboratories with At Least Two Independent
Runs Each. The Rightmost Column Lists the Teratogenicity
Ranking According to Eikel et al. (2006b)
Endpoint Chemical
Mean
(mM)
Lower
bound
(mM)
Upper
bound
(mM) In vivo
ID50(D3)
SProP 0.13 0.09 0.24 þþþþþ
SPenP 0.15 0.09 0.24 þþþþþ
VPA 0.35 0.24 0.53 þþþ
RPenP 1.6 1.0 2.6 þþþ
RProP 2.2 1.4 3.6 þ
2-IP 3.5 2.4 5.2 þ
2-EMP 5.0 3.3 7.6 0
IC50(D3)
SPenP 0.13 0.10 0.17 þþþþþ
SProP 0.55 0.41 0.73 þþþþþ
VPA 1.4 1.1 1.7 þþþ
RPenP 1.9 1.4 2.5 þþþ
RProP 4.5 3.3 6.0 þ
2-IP 4.8 3.7 6.2 þ
2-EMP 5.7 4.4 7.3 0
IC50(3T3)
SPenP 0.21 0.17 0.25 þþþþþ
SProP 1.3 1.1 1.6 þþþþþ
VPA 2.8 2.4 3.2 þþþ
RPenP 2.9 2.5 3.5 þþþ
RProP 4.2 3.5 5.0 þ
2-IP 6.0 5.1 7.1 þ
2-EMP 8.7 7.3 11 0
Note. Note that endpoint values are expressed in millimolar concentrations;
the calculation of the mean values ± 95% conﬁdence interval was based on
their logarithmic endpoint values and was transformed to the original values in
the table. The overall interlaboratory variance (r) of the log10-transformed
effect concentration was r < 0.18 for the ID50(D3) and r < 0.11 for IC50(D3)
and IC50(3T3). The intralaboratory variance was r < 0.25 for the ID50(D3) and
the variance in IC50(D3) and IC50(3T3) values was r < 0.16.
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Figure 3C and Table 1. Most of the IC50(3T3) values were
higher compared with the respective IC50(D3) values, and
ranking of the substances according to their cytotoxicity in 3T3
cells yields a similar ranking as observed with D3 cells: SPenP
<< SProP < VPA < RPenP < RProP < 2-IP < 2-EMP (Table 1).
This similarity in ranking was expected because all compounds
belong to the same substance class.
Multiple Endpoint Comparisons
Multiple pairwise comparisons among the ID50 and IC50
estimates revealed that many but not all observed differences
were signiﬁcant (Fig. 4). For the differentiation endpoint, the
ID50(D3) values of SPenP, SProP, and VPA were not
signiﬁcantly different from each other. In a second group
comprising RPenP, RProP, 2-IP, and 2-EMP, the ID50(D3)
values again were not signiﬁcantly different from each other.
However, each ID50(D3) value from the ﬁrst group was
signiﬁcantly different to any ID50(D3) value in the second
group, demonstrating that the (S)-enantiomers are signiﬁcantly
more potent than corresponding (R)-enantiomers (p < 0.004).
Taken together, for the compound-inherent potency to inhibit
D3 differentiation in vitro, a ranking according to signiﬁcant
differences follows (SPenP, SProP, and VPA) > (RPenP,
RProP, 2-IP, and 2-EMP). With regard to cytotoxicity in D3
cells, VPA and RPenP were not signiﬁcantly different and in
a second group of RProP, 2-IP, and 2-EMP compounds again
were not signiﬁcantly different from each other. All other
IC50(D3) values were signiﬁcantly separated. Therefore, (S)-
enantiomers are signiﬁcantly more cytotoxic than correspond-
ing (R)-enantiomers (p < 0.001) and long-chain derivatives
signiﬁcantly more cytotoxic than corresponding short-chain
congeners (p < 0.001). Thus, taking into account the sig-
niﬁcance of separation, the ranking according to cytotoxicity
reads: SPenP > (SProP and VPA) > (VPA and RPenP) >
(RProP, 2-IP, and 2-EMP).
A comparison of the inhibition of differentiation with the
respective cytotoxicity in D3 cells reveals that the longer chain
compounds RPenP and SPenP act in both assays at similar
concentrations (Fig. 5), suggesting that there is a signiﬁcant
cytotoxic effect contributing to the reported in vivo teratoge-
nicity. The shorter chain analogs RProP and SProP as well as
VPA and to a lesser extend 2-IP exhibit lower ID50(D3) than
IC50(D3) values, arguing for a speciﬁc effect on developmental
differentiation of these compounds (Fig. 5). No systematic bias
was observed.
Prediction Model
The PM in the form of the Fisher functions I, II, and III can
only be used to classify substances into the three classes it was
designed for. Application of the PM to our data classiﬁes 2-
EMP as Class 1 nonembryotoxic, and 2-IP, RProP, RPenP,
VPA, SProP, and SPenP as Class 2 weakly embryotoxic. To
allow for a ranking of the congeners according to their
embryotoxic potency, we used the form of the two canonical
discriminant functions LD1 and LD2 (Fig. 6). SPenP and
SProP, the two (þþþþþ) assigned congeners, are found in
the right, Class 3–facing half of the 95% conﬁdence region of
Class 2, whereas VPA roughly in the middle (Fig. 6). RPenP,
RProP, 2-IP, and 2-EMP are found in the intersection of the
95% conﬁdence regions of Class 1 and Class 2 (Fig. 6). As is
already evident from the ID50(D3), VPA is also separate from
the other two (þþþ) assigned congeners RPenP and RProP in
the PM. 2-IP and 2-EMP are found close to the decision
boundary of Class 2 and Class 1, respectively.
FACS-EST
Recently, we established an abbreviated, molecular-based
protocol to the validated EST, entitled FACS-EST (Seiler et al.,
FIG. 4 Simultaneous conﬁdence intervals for all pairwise comparisons of
ID50 and IC50 mean values of VPA and its congeners obtained in the EST. The
intervals were computed by a robust procedure accounting for heterogeneous
variances. Conﬁdence intervals that do not cross zero indicate statistically
signiﬁcant differences. Data are given as log10-transformed millimolar
concentrations.
FIG. 5 Comparison of differentiation and cytotoxicity of VPA and its
congeners in D3 cells. The difference of the log10-transformed ID50 and IC50
estimates derived by morphological assessment of differentiation of D3 cells
and cytotoxicity in D3 cells for a given substance is plotted against the average
of the two estimates. Values above the dashed zero-difference line represent
substances with a stronger effect on differentiation than on viability.
EMBRYONIC STEM CELL TEST AS TOOL TO STUDY SAR 3652004). All measurements of the FACS-EST are performed after
7 days of treatment, considerably shortening the experimental
protocol. Instead of cardiomyocyte contraction, expression of
the cardiomyocyte marker protein sarcomeric aMHC is
employed as the differentiation endpoint. In a previous study,
we compared the FACS-EST to the validated EST using 10
unrelated compounds (Buesen et al., 2009). Here, we test if the
SAR of the VPA congeners demonstrated by the validated EST
can be also obtained by the FACS-EST. The agreement
between the three endpoints of the two methods was assessed
using Bland-Altman plots (Bland and Altman, 2010)( Fig. 7).
Indeed, a good agreement was found comparing the molecular
endpoint versus the morphological endpoint as indicated by
the inclusion of the zero-difference line by the 95%
conﬁdence interval (Fig. 7A), as well as in the viability
measurements on day 7 versus day 10 of 3T3 cells (Fig. 7C).
A nonsigniﬁcant common bias of 0.1 (log10 scale) was
detected for the two differentiation endpoints (Fig. 7A)a n d
the measurement of viability of 3T3 cells on day 7 versus day
10 (Fig. 7C). This means that for the seven congeners, the
endpoints have a tendency to be more sensitive on day 7, i.e.,
the ID50(D3) and the IC50(3T3) values are on average 21%
lower. Viability of D3 cells exhibited a signiﬁcant common
bias of 0.2 (log10 scale) on day 7 versus day 10 (Fig. 7B). This
means that for the compounds used, this endpoint is more
s e n s i t i v eo nd a y7w i t ha3 7 %l o w e rI C 50(D3) on average.
Analysis of our previous data of 10 different compounds
using Bland-Altman plots did not show a signiﬁcant bias in
any of the endpoints (Buesen et al.,2 0 0 9and not shown).
This suggests that the observed common bias of a higher
sensitivity on day 7 for the VPA congeners is a speciﬁc effect
of this substance class.
DISCUSSION
As part of an effort to comply with the recommendation to
expand the database and thus to increase conﬁdence for
adoption of the EST by regulatory agencies (Marx-Stoelting
et al., 2009), we used the known embryotoxicant VPA and six
of its congeners. All seven compounds are expected to exert
their teratogenic effect directly, i.e., no metabolic activation is
required. This is a prerequisite because the EST in its current
form exhibits no or only little metabolic capacity. The
application of closely related chemical structures in the present
study was also meant to challenge the EST and its modiﬁed
version and to test whether its applicability domain can be
expanded to structural or stereochemical isomers of one
particular compound. In good correlation with in vivo data
(Eikel et al., 2006b; Hauck and Nau, 1992), the SPenP and
SProP exhibited the lowest ID50(D3) and IC50(D3) values, and
2-EMP was the least effective inhibitor of differentiation and
the least cytotoxic compound. In general, the (S)-enantiomers
proved more potent compared with their (R)-stereoisomers in
all three assays used. This result is in excellent agreement with
their relative in vivo teratogenic potency and similar to their
potency of inhibition of histone deacetylases (Eikel et al.,
2006b). With increasing length of the alkyl side chain, VPA
congeners exert increasing antiproliferative activity (Bojic
et al., 1996). Our data reproduce this effect with signiﬁcantly
different IC50(D3) values of both pentyl derivatives compared
with their propyl counterparts in the MTT tests, whereas the
effect of these congeners on differentiation (i.e., the ID50(D3))
was not signiﬁcantly different (Fig. 4). This was expected and
demonstrates that the differentiation endpoint is not directly
affected by cytotoxicity. A comparison of the effects on
differentiation and cytotoxicity in D3 cells revealed that VPA,
FIG. 6 Canonical plot of the VPA data on the two linear discriminant axes. In addition to the VPA congeners (symbols), the substances of the EST
prevalidation set (numbers) and of the validation set (letters) are plotted for comparison. The small points and the large circles represent the group means and the
95% conﬁdence regions for the three toxicity classes, respectively. The dashed lines represent the decision boundary that is used for classiﬁcation into Class 1,
nonembryotoxic (non), Class 2, weakly embryotoxic (weak), and Class 3, strongly embryotoxic (strong). Chemicals of the prevalidation set and the validation
study were classiﬁed as follows: nonembryotoxic, 1–3 and A-G; weakly embryotoxic, 4–6 and H-P; strongly embryotoxic, 7–0 and Q-W.
366 RIEBELING ET AL.SProP, and RProP exhibit a speciﬁc effect on differentiation,
whereas SPenP and RPenP reached their half-maximal effect at
similar concentrations in both assays, and therefore their effect on
differentiation could be primarily because of cytotoxicity (Fig. 5).
In the cardiomyocyte differentiation assay, VPA was nearly
as potent as SPenP and SProP (Fig. 2), and their ID50(D3)
values were not signiﬁcantly different from each other (Fig. 4).
In addition, RPenP exhibited an ID50(D3) value similar to
RProP but not to VPA as in the in vivo ranking (Eikel et al.,
2006b). Recently, a stem cell–based reporter cell line was
generated that exploits a T-cell factor/lymphoid enhancer factor
(LEF)–dependent luciferase reporter to monitor the Wnt/
b-catenin signaling pathway (Uibel et al., 2010). In this so-
called ReProGlo assay, VPA induced reporter activity at lower
concentrations than SProP (Uibel et al., 2010). RPenP was
found to be a ﬁvefold less potent teratogen than VPA in the
cardiomyocyte differentiation assay (Table 1) and similarly
elicited no signiﬁcant response in the ReProGlo system (Uibel
et al., 2010). Taken together, the ID50(D3) values of VPA and
RPenP are signiﬁcantly different, and the two compounds also
elicited different responses in two independent in vitro assays.
A possible explanation for different responses in these in vitro
assays could be differences either in the cell systems used or
in the kinetic behavior of the corresponding compounds.
To address the latter issue further and to adjust for such
differences, methods to predict pharmacokinetic behavior
in silico are currently under development (Verwei et al.,
2006). In line with this suggestion, VPA has been found to
have a threefold shorter systemic half-life in vivo compared
with the alkyne derivatives (Eikel et al., 2006a; Lo ¨scher, 1999).
However, it should be noted that the (þþþ) rating of VPA and
RPenP by Eikel et al. (2006b) comprises an effect of 25–60%
exencephaly rate and thus allows for considerable differences
in the formation of this endpoint.
A small number of studies have addressed SAR in vitro.
When a group of related glycol ether alkoxy acid metabolites
was compared with in vivo data using the EST, the potency
ranking was found to be the same, whereas the relative
differences of in vitro results were smaller than those obtained
in vivo (de Jong et al., 2009). Other studies have investigated
substance families such as heavy metal ions (Imai and
Nakamura, 2006) and nanoparticles of different sizes (Park
et al., 2009); however, no in vivo data were presented. In the
present study, the results cover a somewhat larger
FIG. 7 Bland-Altman plots for inter-method comparisons between the validated EST and the molecular FACS-EST. (A) Inhibition of differentiation as
assessed by morphology versus ﬂow cytometry, (B) cytotoxicity in D3 cells on day 10 versus day 7, and (C) cytotoxicity in 3T3 cells on day 10 versus day 7. The
difference of the log10-transformed ID50 and IC50 estimates derived by the respective assays for a given substance is plotted against the average of the two
estimates. The dashed and dotted lines represent the mean and the 95% conﬁdence interval (mean ± 1.96 3 SD) of the difference, respectively.
EMBRYONIC STEM CELL TEST AS TOOL TO STUDY SAR 367concentration range of nearly two magnitudes compared with
about one magnitude (0.25–3 mmol/kg) for the in vivo ranking
(Eikel et al., 2006b). However, because of the variance in the
differentiation assay, some values do not separate signiﬁcantly.
The ranking according to their respective ID50 and IC50 values
nevertheless provides a valuable tool to monitor the relative
effects of the congeners, as it resembles the ranking according
to their teratogenic activity obtained from in vivo experiments.
The three functions of the PM of the EST have been
designed to classify substances according to the criteria deﬁned
for the ECVAM international validation study (Brown, 2002;
Scholz et al., 1999), and their application to an unrelated set of
criteria does not yield satisfying results (Marx-Stoelting et al.,
2009). To allow for visualization as well as gradual ranking of
the PM data, we used its canonical form (Fig. 6). The
congeners distribute in good agreement with the in vivo
ranking. 2-EMP (0) is nonembryotoxic in the PM, and 2-IP (þ)
is weakly embryotoxic with its data point falling closely to the
decision boundary of Class 1 and Class 2 (Fig. 6). RPenP and
RProP fall more to the right, indicating higher potency, but
separate from the other (þþþ) ranked substance VPA. The
possible reasons for this separation have been discussed for the
ID50(D3) above. The two (þþþþþ) ranked congeners SProP
and SPenP clearly separate to the right, which is in good
agreement with their high potency. The classiﬁcation by Brown
does not classify a substance based solely on the severity or
breadth of its embryotoxic effects (Brown, 2002). Thus, it can
be explained that Eikel et al. (2006b) ranked these two
congeners as of very high teratogenicity based on their effects
in a single mouse strain, whereas the PM predicts them as Class
2, weakly embryotoxic. It should be stressed that the near linear
separation of the congeners on the ﬁrst canonical discriminant
function LD1, caused by the similarity in the values of the three
endpoints, is in consequence of the shared mode of action. The
substances of the prevalidation set and the validation study
exhibit a wide spread on the second discriminant function, and
this affects their classiﬁcation especially at the decision
boundaries (Fig. 6), underscoring the importance of all three
endpoints for a balanced decision.
It is explicitly stated in the Registration, Evaluation,
Authorisation and Restriction of Chemicals (REACh) legisla-
ture, Annex XI.1.2, that in vitro methods can be included in
a weight of evidence approach, and in Annex XI.1.4, it is stated
that in vitro methods can be used for identifying a certain
dangerous property. Furthermore, Annex XI.1.5 allows for
grouping of substances whose properties are likely following
a regular pattern. The validated EST is a suitable method in the
sense of the REACh legislature as it has been validated by
ECVAM (Genschow et al., 2004). However, the lack of
metabolic activity of the validated EST means that the
prediction of Class 1 (nonembryotoxic) for a substance is
strictly valid only for the substance at hand. Metabolism of the
substance and the effects of metabolites have to be tested
separately. Conversely, a Class 2 or Class 3 predicted
substance might be rapidly metabolized to a Class 1 substance
in vivo or might not be able to cross the placental barrier. Thus,
the validated EST cannot function as a stand-alone method to
assess embryonic toxicity.
Recent efforts have focused on adapting the validated EST to
the requirements of high-throughput screening applications.
We investigated the use of molecular endpoints by ﬂow
cytometry and identiﬁed aMHC to be a valuable biomarker of
cardiomyocyte differentiation (Seiler et al., 2004). Using a set
of 10 well-known embryotoxicants that encompasses the full
range of embryotoxic potencies, the FACS-EST exhibited the
same sensitivity as the validated EST (Buesen et al., 2009).
Here, the seven VPA congeners were tested in the FACS-EST,
and the resulting ID50 and IC50 values were compared to the
results of the validated EST (Fig. 7). Our results conﬁrm that
the FACS-EST is in good agreement with the validated EST.
Because the FACS-EST is adaptable to other stem cell
differentiation protocols, its applicability domain could be
easily expanded to other cell lineages. To this end, tran-
scriptomics and proteomics approaches can reveal new markers
suitable as molecular endpoints (Groebe et al., 2010; van
Dartel et al., 2010). Another approach was recently developed
by Uibel et al. (2010), which takes advantage of a reporter stem
cell line in the so-called ReProGlo assay (cf., above). By
testing a similar set of molecules as in this study, however,
only SPenP, SProP, and VPA yielded a signiﬁcant effect on
reporter gene activity. Conversely, RPenP, RproP, and 2-EMP
were without effect on luciferase expression, and among all
VPA derivatives tested, only SPenP revealed a weak effect on
cell viability. The lower sensitivity of the ReProGlo system
compared with the EST or FACS-EST is most probably
because of the much shorter incubation time of 24 h.
During the validation of the EST and the development of the
FACS-EST, the test compounds chosen were recruited from
a wide range of different chemical classes to avoid bias because
of structure-function relationships. In the present study, we
demonstrate that the EST is suited to distinguish teratogenic
potencies within a group of closely related VPA derivatives. The
resulting ranking is in excellent agreement to the ranking
obtained in vivo using the NMRI-exencephaly-mouse model.
However, it is important to evaluate both the chemical-mediated
effects on cardiomyocyte differentiation and cell viability, as
was demonstrated by the differential effects of chirality and
chain length on differentiation and cytotoxicity. Similar results
to the validated EST were obtained using the FACS-EST. Our
data thus strengthen the applicability of the EST and further
conﬁrm the FACS-EST as an efﬁcient and reliable replacement
of the EST toward a higher throughput.
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